Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.
作者信息
Taylor Alison, Rudd Christopher E
机构信息
Leeds Institute of Medical Research, University of Leeds, School of Medicine, Wellcome Trust Brenner Building, St James's University Hospital, LEEDS LS9 7TF, UK.
Division of Immunology-Oncology Research Center, Maisonneuve-Rosemont Hospital, Montreal, Quebec H1T 2M4, Canada.
出版信息
J Immunol Sci. 2019 May 7;3(1):9-12. doi: 10.29245/2578-3009/2019/1.1167.
Abstract
摘要
相似文献
1
Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy.
J Immunol Sci. 2019 May 7;3(1):9-12. doi: 10.29245/2578-3009/2019/1.1167.
2
Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.
Cancer Res. 2018 Feb 1;78(3):706-717. doi: 10.1158/0008-5472.CAN-17-0491. Epub 2017 Oct 20.
3
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Oncogene. 2020 May;39(19):3939-3951. doi: 10.1038/s41388-020-1270-z. Epub 2020 Mar 23.
4
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156.
5
Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
FEBS Open Bio. 2021 Mar;11(3):911-920. doi: 10.1002/2211-5463.13088. Epub 2021 Jan 31.
6
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC tumors respond to PD1/PD-L1 blockade therapy.
J Immunother Cancer. 2019 Aug 26;7(1):223. doi: 10.1186/s40425-019-0693-y.
7
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor.
Bio Protoc. 2023 Aug 5;13(15):e4765. doi: 10.21769/BioProtoc.4765.
8
Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy.
ACS Appl Mater Interfaces. 2020 Sep 9;12(36):40085-40093. doi: 10.1021/acsami.0c11156. Epub 2020 Aug 27.
9
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 Activated T Cells.
Cancer Discov. 2021 May;11(5):1100-1117. doi: 10.1158/2159-8290.CD-20-1445. Epub 2021 Jan 8.
10
Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor.
Mol Ther. 2025 Feb 5;33(2):723-733. doi: 10.1016/j.ymthe.2024.12.044. Epub 2024 Dec 31.
引用本文的文献
1
Comment on: Glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation.
Cell Mol Immunol. 2025 May;22(5):557-558. doi: 10.1038/s41423-025-01277-8. Epub 2025 Apr 2.
本文引用的文献
1
Effects of Glycogen Synthase Kinase-3β Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.
J Immunother. 2018 Sep;41(7):319-328. doi: 10.1097/CJI.0000000000000234.
2
Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy.
Cancer Res. 2018 Feb 1;78(3):706-717. doi: 10.1158/0008-5472.CAN-17-0491. Epub 2017 Oct 20.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.
5
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.
6
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.
7
Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
J Dermatol. 2017 Aug;44(8):e196-e197. doi: 10.1111/1346-8138.13840. Epub 2017 Apr 9.
8
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28.
9
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
10
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
BioDrugs. 2016 Dec;30(6):571-584. doi: 10.1007/s40259-016-0204-3.
Zotero 插件